Topic
FDA
Food and Drug Administration
Recent coverage of FDA from across the web.
-
Former top US food safety official says US mismanagement of cyclospora is approaching ‘a catastrophic level’ -
FDA advisers say six popular peptides can be compounded. Here are the issues they considered.
-
FDA advisory panel narrowly rejects compounding of one peptide, backs two others -
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here’s what happens next.
-
STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides -
STAT+: Popular insulin product enters shortage as other pens leave market -
Expect a clash at today’s FDA peptide panel -
FDA panel considers easing peptide restrictions
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow